Favipiravir is a novel antiviral drug approved for influenza treatment in Japan. Little is known about favipiravir pharmacokinetics in critically ill patients. Here, we report a patient with influenza treated with favipiravir and undergoing continuous venovenous haemofiltration (CVVH) on the Intensive Care Unit of a tertiary hospital in the Netherlands. Pharmacokinetic analyses showed increased clearance and decreased plasma levels compared to healthy volunteers. CVVH has no clinically relevant contribution to total clearance. Despite susceptibility to favipiravir, the influenza virus was not cleared. A multi-disciplinary approach is needed to ensure optimal favipiravir treatment in critically ill patients.

中文翻译：

---

法维拉韦在重症流感患者连续静脉血液滤过期间的药代动力学。

Favipiravir是在日本获准用于流感治疗的新型抗病毒药。关于Favipiravir在危重患者中的药代动力学知之甚少。在这里，我们报告了一名接受favipiravir治疗并在荷兰一家三级医院的加护病房接受连续静脉血液滤过（CVVH）感染的流感患者。药代动力学分析显示，与健康志愿者相比，清除率增加且血浆水平降低。CVVH对总清除率无临床意义的贡献。尽管对favipiravir敏感，但尚未清除流感病毒。需要一种多学科的方法来确保重症患者的最佳依维拉韦治疗。